Cosciens Biopharma Inc. declined 4.00% in premarket trading. The company announced a corporate restructuring during and continuing after Q2 2025, resulting in a 27% workforce reduction to support leaner operations. Additionally, the company plans to voluntarily delist from Nasdaq while retaining its listing on the TSX.
Comments
No comments yet